Micronized vs ultra-micronized PEA: what the particle-size data actually shows
Micronising palmitoylethanolamide demonstrably improves oral absorption. Ultra-micronising it beyond that point demonstrably does not, at least in the comparative pharmacokinetic data. Here is the evidence for both statements, and how to write a specification that holds a supplier to a number.
Published July 2026 by the PEAOID technical team · reviewed against the primary literature
The problem particle size solves
Palmitoylethanolamide has a log P of roughly 6 and is practically insoluble in water — aqueous solubility sits in the low milligrams per liter. That makes oral absorption dissolution-rate limited: the molecule cannot be absorbed until the crystal dissolves, and the crystal dissolves at a rate governed by its surface area.
This is textbook Noyes–Whitney behavior, and it is exactly the problem that micronization exists to solve. Break a large crystal into many small ones and total surface area rises steeply while the mass stays the same. Dissolution accelerates. More of the dose gets absorbed inside the window available before it leaves the absorption site.
Which is why “micronized” became a selling point in this category — and why, absent a number attached to it, the word is close to meaningless.
What the three grades actually mean
| Grade | Typical particle size | Description |
|---|---|---|
| Normal / unmicronized | D50 ≈ 100–200 µm | The material as it comes out of crystallization and drying. Large, irregular, plate-like crystals with low specific surface area. Sold as normal-grade or plain “PEA powder”, sometimes at 80 mesh. |
| Micronized (PEA-m) | D50 ≈ 2–6 µm D90 ≤ 10 µm | Jet-milled. The particle-size class used in the majority of published human PEA studies, and what most on-pack “micronized PEA” claims are intended to mean. |
| Ultra-micronized (PEA-um) | D90 < 6 µm majority < 2 µm | Milled further, to a tighter distribution weighted below two microns. The class used in much of the European clinical and veterinary literature. |
An honest caveat about these numbers
There is no pharmacopoeial definition of “micronized” or “ultra-micronized” for palmitoylethanolamide. The ranges above reflect industry convention and the descriptions used in the published comparative studies, not a codified standard. Which is precisely why you should ask any supplier — us included — for a measured laser-diffraction distribution rather than accepting the adjective.
The evidence that micronising works
The pivotal study is Impellizzeri and colleagues, published in the Journal of Neuroinflammation in 2014. They compared micronized PEA, ultra-micronized PEA and a non-micronized reference material in a rat carrageenan-induced inflammatory pain model.
Given orally, micronized and ultra-micronized PEA significantly reduced paw edema, thermal hyperalgesia, inflammatory cell infiltration and myeloperoxidase activity. The non-micronized material failed to produce a significant reduction in thermal hyperalgesia or neutrophil infiltration at the same oral dose.
Given intraperitoneally — bypassing the gastrointestinal tract entirely — all three forms, including the non-micronized material, were equally effective.
That second experiment is the one that matters. It rules out any pharmacological difference between the forms and localises the entire effect to gastrointestinal absorption. The molecules are identical; only their ability to get into the body differs.
Pharmacokinetic work points the same way. In rats given 30 mg/kg, ultra-micronized PEA reached a peak plasma concentration of 5.4 pmol/mL at five minutes against 1.1 pmol/mL for naive PEA — roughly five-fold. In beagle dogs at 30 mg/kg, ultra-micronized PEA produced approximately a five-fold increase in blood concentration over non-micronized material, peaking at 55–60 pmol/mL at one to two hours.
Where the returns stop
Here is the part that ingredient marketing tends to leave out.
Della Valle and colleagues compared micronized against ultra-micronized PEA in beagle dogs at 15 mg/kg. The serum peaks were 22.2 and 22.4 pmol/mL respectively at one hour, both returning to baseline by two hours. Statistically and practically indistinguishable.
What that implies
The large, well-replicated step change is from unmicronized to micronized. Once particles are small enough to dissolve within the available absorption window, making them smaller stops buying you exposure — the rate-limiting step has moved elsewhere.
This does not make ultra-micronized material pointless. There are three good reasons to specify it: uniformity of content in very small or thin dosage forms such as oral films and sublinguals; matching the exact grade used in a body of European clinical work you want to reference; and premium positioning where the brand narrative is built on bioavailability. Those are legitimate. “It absorbs meaningfully better than micronized” is not well supported by the comparative data.
Beyond milling: the other approaches
Particle-size reduction is not the only route to better dissolution. Several formulation technologies are commercially established:
| Approach | How it works | Published human data |
|---|---|---|
| Dispersion systems e.g. LipiSperse | A polar-lipid and surfactant system that prevents micronized crystals from re-agglomerating in the gut, preserving effective surface area. | Randomized crossover in 28 healthy adults, single 300 mg dose: Cmax 11.12 vs 7.96 pmol/mL (1.4×) and AUC0–4h 1,942 vs 1,117 (1.75×) against standard PEA, both p<0.05. |
| Phospholipid complex phytosome-type | PEA complexed with phospholipids to improve solubilisation and systemic exposure. | A 2025 Biomedicines paper reports improved solubility and systemic exposure with clinical support in chronic neuropathic low back pain. |
| Liposomal | Encapsulation in phospholipid vesicles. | Commercial products exist; we could not locate independently published human bioavailability data specific to liposomal PEA. Treat absorption claims here with caution. |
| Co-micronization with luteolin or polydatin | Two actives milled together to a shared distribution rather than dry blended, producing a composite particle. | A rat inflammation study found co-micronized PEA/polydatin superior to a simple association of the two. The European clinical work on PEA-luteolin uses co-processed material. |
| Supercritical fluid processing | CO2 antisolvent techniques to produce fine particles without mechanical milling. | Described in the process literature specifically because PEA is difficult to micronise conventionally. Not a mainstream commercial route. |
How to specify particle size properly
If you are writing a purchase specification for PEA, these are the clauses that will save you an argument later.
- Name the method. Laser diffraction, with the dispersion medium and dispersant stated. Dynamic light scattering and sieve analysis give different answers on the same material.
- Specify three points, not one. D10, D50 and D90. A supplier can hit a D50 target while shipping a distribution with a long coarse tail.
- Require the result on the certificate of analysis, per batch, as a number. Not “micronized”, not “complies”.
- Ask for the distribution curve for the first few lots so you can see the shape rather than three points on it.
- Specify bulk and tapped density too. Milled PEA is fluffy and static-prone; your encapsulation team needs this before the drum arrives, not after.
- Agree the retest position. Milled powders can agglomerate over time in poor storage. Ask whether PSD is re-tested at retest date.
Choosing a grade for a real product
| If you are making… | Specify | Because |
|---|---|---|
| Hard capsules, 300–600 mg | Micronized | Matches the grade used in most published human work; dissolution is not the limiting factor above micronized. |
| Tablets | Micronized | Better compaction behavior than ultra-fine material, which tends to entrain air and cap. |
| Gummies | Micronized | Suspends evenly in the depositor; normal grade sediments and gives poor content uniformity. |
| Oral films, sublinguals | Ultra-micronized | Content uniformity in a thin film is a particle-size problem before it is anything else. |
| Topical creams | Ultra-micronized | Grittiness is the failure mode; finer particles avoid a sensory defect. |
| Beverages, RTD shots | CWD grade | Milling alone will not solve wetting. You need a dispersion or emulsification approach. |
| Stick packs, effervescent | Normal or micronized | Effervescence assists wetting; the economics often favor the coarser grade here. |
| Pet soft chews | Normal or micronized | Cold-formed chews tolerate coarser material; micronized improves per-piece dose uniformity in small chews. |
See PEAOID grades and particle-size specifications
References
- Impellizzeri D, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 2014;11:136. PMID 24581357
- Petrosino S, et al. Oral ultramicronized palmitoylethanolamide: plasma and tissue levels and spinal anti-hyperalgesic effect. PMID 29615912
- Cerrato S, et al. Canine pharmacokinetics of ultramicronized PEA, 2012; and Della Valle F, et al., comparative micronized vs ultramicronized canine pharmacokinetics, 2013 — both summarized in Beggiato S, Tomasini MC, Ferraro L, Front Pharmacol 2019;10:821.
- Briskey D, et al. Increased absorption of palmitoylethanolamide using a novel dispersion technology system (LipiSperse). J Nutraceuticals and Food Science.
- Phospholipid-based delivery system optimizes the solubility and systemic exposure of palmitoylethanolamide. Biomedicines 2025.
- A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. Eur J Pharmacol.
- Supercritical fluids based techniques to process pharmaceutical products difficult to micronize: palmitoylethanolamide.
Request a specification, a sample, or a quotation
Send us your target dose, format and volume. Our technical team replies with a full documentation pack — specification, method summary, batch CoA and regulatory dossier — within one business day.